Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study
Langenbeck's Archives of Surgery · 2024
DOI: 10.1007/s00423-024-03249-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Langenbeck's Archives of Surgery, 2024. Verfasst von Tao Bai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Key Laboratory of High-Incidence-Tumor Prevention and Treatment of the Ministry of Education, Guangxi Medical University Training Program for Distinguished Young Scholars.
Abstract (Originalsprache)
BACKGROUND: This study was recruited to compare the efficacy and safety of radiotherapy (RT) and transarterial chemoembolization (TACE) as postoperative adjuvant therapy after narrow-margin hepatectomy in hepatocellular carcinoma (HCC) patients. METHODS: This single-center prospective randomized study was conducted in the Cancer Hospital, Guang Xi Medical University, Nanning. A total of 72 patients who received treatment in this hospital between August 2017 and July 2019 were included and randomly allocated to TACE group (n = 48) and RT group (n = 24). Next, overall survival (OS) and progression-free survival (PFS) rates, recurrence patterns, financial burden, and safety were evaluated. RESULTS: The difference between the RT and TACE groups was not significant in one-, three-, and five-year OS (87.5%, 79.0%, and 62.5% vs. 93.8%, 75.9%, and 63.4%, respectively, P = 0.071) and PFS rates (79.0%, 54.2%, and 22.6% vs. 75.0%, 47.9%, and 32.6%, respectively, P = 0.071). Compared to the TACE group, the RT group had significantly lower intrahepatic recurrence rate (20.8% vs. 52.1%, P = 0.011), higher extrahepatic recurrence rate (37.5% vs. 14.6%, P = 0.034), and no marginal and diffuse recurrences (0% vs. 16.7%, P < 0.05). The mean overall treatment cost was higher (¥62,550.59 ± 4397.27 vs. ¥40,732.56 ± 9210.54, P < 0.01), the hospital stay (15.1 ± 3.7 vs. 11.8 ± 4.1 days, P < 0.01) was longer, and the overall treatment stay (13.3 ± 5.3 vs. 41.29 ± 12.4 days, P < 0.01) was shorter in the TACE group than in the RT group. Besides, both groups did not exhibit significant differences in the frequency and severity of adverse events. CONCLUSION: Both adjuvant TACE and RT can better the OS and PFS of patients with HCC. However, RT has a significantly better performance than TACE in terms of improving intrahepatic recurrence rate, treatment cost and hospital stay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. lilequngx@163.com.
- Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor(Guangxi Medical University), Nanning, Guangxi, China. lilequngx@163.com.
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. wufx2013@163.com.
Förderung
- Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education
- Key Laboratory of High-Incidence-Tumor Prevention and Treatment of the Ministry of Education
- Guangxi Medical University Training Program for Distinguished Young Scholars
Zitieren
APA
Bai, T., Tang, Z. H., Wang, X. B., Chen, J., Ye, J. Z., Lu, S. L., Wei, M., Wu, F. X., & Li, L. Q. (2024). Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study. Langenbeck's Archives of Surgery. https://doi.org/10.1007/s00423-024-03249-4
Vancouver
Bai T, Tang ZH, Wang XB, Chen J, Ye JZ, Lu SL, et al. Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study. Langenbeck's Archives of Surgery. 2024. doi:10.1007/s00423-024-03249-4
BibTeX
@article{Bai2024,
author = {Bai, Tao and Tang, Zhi-Hong and Wang, Xiao-Bo and Chen, Jie and Ye, Jia-Zhou and Lu, Shao-Long and Wei, Meng and Wu, Fei-Xiang and Li, Le-Qun},
title = {Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study},
journal = {Langenbeck's Archives of Surgery},
year = {2024},
doi = {10.1007/s00423-024-03249-4}
}
EUVIMED